Prescription trends and costs of diabetes medications in Australia between 2003 and 2019: an analysis and review of the literature

Abstract

Background Since the turn of the century, the prevalence of diabetes mellitus in Australia has increased, primarily due to rising rates of Type 2 diabetes. Simultaneously, the landscape of diabetes medications has evolved significantly. The change in prescribing trends and public spending on diabetes medications within Australia during this period are not well defined. Aims To establish the frequency and cost of dispensed diabetes medications in the Australian public healthcare system between 2003 and 2019. Methods We performed a longitudinal nationwide observational study using data obtained from the Pharmaceutical Benefits Scheme (PBS) and Medicare Benefits Schedule websites, which contain information on frequency and spending of diabetes medications dispensed in Australia. Results The total number of PBS‐subsidised prescriptions dispensed for diabetes increased from 5 218 690 in 2003 to 12 188 568 in 2019, and spending increased from $117 241 031 to $598 904 983. Of the non‐insulin agents, metformin was consistently the most frequently dispensed agent, with a rapid growth in metformin combination tablets. Dispensation of sulphonylureas and thiazolidinediones have declined, with a simultaneous increase in dipeptidyl peptidase‐4 inhibitors, sodium‐glucose co‐transporter 2 inhibitors and glucagon‐like peptide‐1 receptor agonists. Conclusions Our data show a large growth in the use of diabetes medications between 2003 and 2019. The rapid growth in dispensing of drugs with proven cardiovascular and renal benefits reflect the evolving approach of diabetes treatment, from a historical approach targeting glycaemic control alone, to a modern individualised approach targeting specific co‐morbidities.

Bioequivalence Evaluation in Healthy Volunteers: New Generic Formulations of Sitagliptin and Sitagliptin–Metformin Fixed-Dose Combination Compared with the Originator Products

“…Patients with T2D who are already treated with the individual products can be switched to the FDC of sitagliptin/metformin [ 22 ]. In the past decade the use of combination tablets for the treatment of T2D has increased [ 23 ]. Using FDC products can reduce the complexity of drug intake by decreasing the number of tablets to be taken, which can improve treatment adherence [ 24 , 25 ] and ultimately treatment outcomes; as such, reducing the number of tablets to be taken may be beneficial for patients on polypharmacy.…”

Patterns of metformin use and glycated haemoglobin trends among patients with newly diagnosed type 2 diabetes in Alberta, Canada

“…Since its rediscovery and first reported use to treat diabetes in 1957, metformin remains the most widely used oral antihyperglycaemic agent in the world. [1][2][3] It has a strong evidence base proving its efficacy and long-term safety for type 2 diabetes, and accordingly, is often considered the first-line therapy in this population, except for those with contraindications or who have clear indications for an alternate therapy (i.e. sodium-glucose cotransporter 2 inhibitors for cardiovascular disease).…”

Bariatric surgery: a call for greater access to coordinated surgical and specialist care in the public health system

“…The Australian Burden of Disease Study highlights obesity as the second largest risk for fatal disease and largest risk for non‐fatal disease over the past 15 years 2 . While death rates have been mitigated by a 35% increase in cardiovascular medicine prescriptions and a doubling of diabetes management therapies, 3 our ability to successfully maintain this approach is likely to be overrun as Australian obesity rates climb to over 40% within a decade. Aside from the individual health impact, obesity creates significant community cost implications — direct costs are estimated to be $5.4 billion and indirect costs a further $6.4 billion per year in Australia 4 .…”